Genomma Lab InternacionalB de CV (MEX:LABB) Piotroski F-Score: 6 (As of Aug. 10, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
59 GF Score
Price MXN14.37
GF Value MXN17.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Piotroski F-Score?

Genomma Lab InternacionalB de CV MEX:LABB +1.84% 59 Piotroski F-Score is 6 as of Aug. 10, 2026, which is at its 10-year median of 6.00. GuruFocus rates MEX:LABB with a GF Score™ of 59/100 and a GF Value™ of MXN17.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 977 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 78.71% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's Piotroski F-Score or its related term are showing as below:

MEX:LABB' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Genomma Lab InternacionalB de CV was 8. The lowest was 3. And the median was 6.

Genomma Lab InternacionalB de CV  (MEX:LABB) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Genomma Lab InternacionalB de CV Piotroski F-Score Related Terms


Genomma Lab InternacionalB de CV Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Piotroski F-Score Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 7.00 6.00 7.00 5.00

Genomma Lab InternacionalB de CV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 5.00 5.00 4.00 6.00

MEX:LABB vs ZTS, UTHR, VTRS: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Piotroski F-Score falls into.


MEX:LABB
59GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 434.066 + 319.636 + 494.647 + 374.493 = MXN1,623 Mil.
Cash Flow from Operations was 440.33 + 1255.694 + -229.167 + 383.158 = MXN1,850 Mil.
Revenue was 4441.43 + 4016.967 + 4190.623 + 4397.037 = MXN17,046 Mil.
Gross Profit was 2836.157 + 2449.239 + 2657.588 + 2838.587 = MXN10,782 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(24244.526 + 23608.38 + 23690.512 + 24800.496 + 24194.989) / 5 = MXN24107.7806 Mil.
Total Assets at the begining of this year (Jun25) was MXN24,245 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,566 Mil.
Total Current Assets was MXN13,195 Mil.
Total Current Liabilities was MXN7,187 Mil.
Net Income was 660.06 + -170.689 + 498.719 + 354.966 = MXN1,343 Mil.

Revenue was 5092.514 + 4665.574 + 4406.326 + 4676.435 = MXN18,841 Mil.
Gross Profit was 3272.001 + 2941.672 + 2767.321 + 2969.415 = MXN11,950 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(21984.814 + 23508.259 + 23017.803 + 24080.376 + 24244.526) / 5 = MXN23367.1556 Mil.
Total Assets at the begining of last year (Jun24) was MXN21,985 Mil.
Long-Term Debt & Capital Lease Obligation was MXN4,964 Mil.
Total Current Assets was MXN13,289 Mil.
Total Current Liabilities was MXN7,266 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 1,623. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 1,850. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=1622.842/24244.526
=0.06693643

ROA (Last Year)=Net Income/Total Assets (Jun24)
=1343.056/21984.814
=0.06109017

Genomma Lab InternacionalB de CV's return on assets of this year was 0.06693643. Genomma Lab InternacionalB de CV's return on assets of last year was 0.06109017. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Genomma Lab InternacionalB de CV's current Net Income (TTM) was 1,623. Genomma Lab InternacionalB de CV's current Cash Flow from Operations (TTM) was 1,850. ==> 1,850 > 1,623 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=4566.034/24107.7806
=0.18940084

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=4963.546/23367.1556
=0.2124155

Genomma Lab InternacionalB de CV's gearing of this year was 0.18940084. Genomma Lab InternacionalB de CV's gearing of last year was 0.2124155. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=13194.97/7186.961
=1.83595959

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=13288.941/7266.278
=1.82885117

Genomma Lab InternacionalB de CV's current ratio of this year was 1.83595959. Genomma Lab InternacionalB de CV's current ratio of last year was 1.82885117. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Genomma Lab InternacionalB de CV's number of shares in issue this year was 0. Genomma Lab InternacionalB de CV's number of shares in issue last year was 973.793. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=10781.571/17046.057
=0.63249648

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=11950.409/18840.849
=0.63428187

Genomma Lab InternacionalB de CV's gross margin of this year was 0.63249648. Genomma Lab InternacionalB de CV's gross margin of last year was 0.63428187. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=17046.057/24244.526
=0.7030889

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=18840.849/21984.814
=0.85699379

Genomma Lab InternacionalB de CV's asset turnover of this year was 0.7030889. Genomma Lab InternacionalB de CV's asset turnover of last year was 0.85699379. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+0+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Genomma Lab InternacionalB de CV has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Piotroski F-Score of 6 as of Aug. 10, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is near median its historical median of 6.00. Over the past decade, Genomma Lab InternacionalB de CV's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #208 out of 977 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Genomma Lab InternacionalB de CV's Piotroski F-Score too high?
Genomma Lab InternacionalB de CV's current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Genomma Lab InternacionalB de CV's value of 6 is 20% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #208 out of 977 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #208 out of 977 companies for Piotroski F-Score. This places Genomma Lab InternacionalB de CV in the top 21% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Genomma Lab InternacionalB de CV's value of 6 is 20% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 977 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.13, compared to a current price of MXN14.37 — trading 16.1% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Drug Manufacturers industry median of 5.00. Genomma Lab InternacionalB de CV's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Piotroski F-Score is 6 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN14.37 is trading 16.1% below its estimated GF Value™ of MXN17.13. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: MXN17.13 vs. price of MXN14.37 (16.1% below fair value)
  • GF Score™: 59/100 with 3 warning signs
  • Industry Position: 20% above the Drug Manufacturers median (#208 of 977)

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
59GF Score

Get the complete analysis for MEX:LABB

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN14.37
Price
MXN17.13
GF Value